3 completed, 1 active not recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Refractory Lymphoplasmacytic Lymphoma: new trials by email Literature Review of Refractory Lymphoplasmacytic Lymphoma trials Research Report on Refractory Lymphoplasmacytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 73 | 2008-06-25 | 2019-12-27 |
Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Waldenstrom Macroglobulinemia (2) · Burkitt Lymphoma (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Chronic Disease (3) · Disease Attributes (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Leukemia (3)
Cyclophosphamide (2) · fludarabine phosphate (2) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Cyclosporins (1) · Immunotherapy, Adoptive (1) · Lenalidomide (1) · Leukapheresis (1) · Mycophenolic Acid (1) · Nivolumab (1) · Whole-Body Irradiation (1) · ibrutinib (1) · idelalisib (1) · pembrolizumab (1)
Fred Hutchinson Cancer Center (2) · David Bond, MD (1) · Mayo Clinic (1)
United States (4)
David Bond, MD (1) · Mazyar Shadman (1) · Rachel Salit (1) · Wei Ding (1)
P30CA015704 (1), P50CA097274 (1)